Research programme: cardiovascular disease therapies - Amarin

Drug Profile

Research programme: cardiovascular disease therapies - Amarin

Alternative Names: EPA derivatives - Amarin; Ethyl eicosapentaenoic acid derivatives - Amarin; Unsaturated fatty acid derivatives - Amarin

Latest Information Update: 28 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amarin Corporation; Scarista
  • Developer Amarin Corporation
  • Class
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hyperlipidaemia; Metabolic syndrome

Most Recent Events

  • 16 Mar 2015 Pharmacodynamics data from a preclinical trial in Atherosclerosis presented at the 64th Annual Scientific Session of the American College of Cardiology (ACC-2015)
  • 04 Mar 2008 Amarin has licensed intellectual property from Scarista relating to lipid science worldwide
  • 29 Nov 2007 The first product from this programme has entered clinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top